CA2976577C - MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES - Google Patents
MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLESInfo
- Publication number
- CA2976577C CA2976577C CA2976577A CA2976577A CA2976577C CA 2976577 C CA2976577 C CA 2976577C CA 2976577 A CA2976577 A CA 2976577A CA 2976577 A CA2976577 A CA 2976577A CA 2976577 C CA2976577 C CA 2976577C
- Authority
- CA
- Canada
- Prior art keywords
- hsa
- mir
- mirs
- diagnostic
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500079 | 2015-02-11 | ||
| DKPA201500079 | 2015-02-11 | ||
| DKPA201500825 | 2015-12-21 | ||
| DKPA201500825 | 2015-12-21 | ||
| PCT/DK2016/050032 WO2016127998A1 (en) | 2015-02-11 | 2016-02-05 | A microrna-based method for early detection of prostate cancer in urine samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2976577A1 CA2976577A1 (en) | 2016-08-18 |
| CA2976577C true CA2976577C (en) | 2024-11-19 |
Family
ID=55435920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2976577A Active CA2976577C (en) | 2015-02-11 | 2016-02-05 | MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10400288B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3256602B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018504915A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2976577C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2749651T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016127998A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3262186B1 (en) | 2015-02-27 | 2019-04-03 | QIAGEN GmbH | A microrna-based method for assessing the prognosis of a prostate cancer patient |
| WO2018049506A1 (en) * | 2016-09-14 | 2018-03-22 | Ontario Institute For Cancer Research (Oicr) | Mirna prostate cancer marker |
| CN106834470A (zh) * | 2017-02-17 | 2017-06-13 | 张灏 | miRNA在制备癌症诊断试剂盒中的用途 |
| JP7118046B2 (ja) * | 2017-03-02 | 2022-08-15 | 第一三共株式会社 | オピオイド薬の治療有効性を予測するためのｍｉｃｒｏＲＮＡバイオマーカー |
| CN107488734B (zh) * | 2017-10-10 | 2019-11-05 | 广州医科大学附属第二医院 | miR-19a-3p在制备前列腺癌骨转移诊断试剂和治疗药物中的应用 |
| CN107663541A (zh) * | 2017-10-31 | 2018-02-06 | 温州医科大学 | 一种用于诊断原发性肝癌的特异性生物标志物及其筛选方法与应用 |
| CA3096419A1 (en) * | 2018-04-10 | 2019-10-17 | Unity Health Toronto | Methods for monitoring and treating prostate cancer |
| JPWO2019220759A1 (ja) * | 2018-05-17 | 2021-07-15 | Ｓｔｅｍｃｅｌｌ株式会社 | がんの分析方法、がんの分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体 |
| CN108424962B (zh) * | 2018-05-25 | 2021-08-03 | 中国人民解放军陆军军医大学 | 系膜增生性肾小球肾炎的miRNA检测标志物及其诊断试剂盒 |
| CN109112109A (zh) * | 2018-07-27 | 2019-01-01 | 浙江大学 | 一种骨髓间充质干细胞外泌体的改造方法 |
| EP3699300A1 (en) * | 2019-02-22 | 2020-08-26 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer |
| AU2020241720A1 (en) | 2019-03-15 | 2021-10-14 | Mir Scientific, Llc | Methods for predicting prostate cancer and uses thereof |
| EP3719144A1 (en) * | 2019-04-05 | 2020-10-07 | Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) | Mir-151a-3p as an universal endogenous control for exosome cargo normalization |
| JP2020195314A (ja) * | 2019-05-31 | 2020-12-10 | 医薬資源研究所株式会社 | 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体 |
| CN115038796A (zh) * | 2019-09-09 | 2022-09-09 | 科莱鹤株式会社 | 含有微小rna的体液提取物 |
| CN111118165B (zh) * | 2020-03-04 | 2023-04-07 | 朱伟 | 一种与前列腺癌辅助诊断相关的血清miRNA标志物及其应用 |
| CN112094910B (zh) * | 2020-09-25 | 2023-03-24 | 无锡市中医医院 | 一种用于前列腺癌患病风险评估的miRNA标志物 |
| CN112795657A (zh) * | 2021-03-22 | 2021-05-14 | 中国农业大学 | miRNA在制备诊断或辅助诊断哺乳动物前列腺癌症产品中的应用 |
| US20240229116A9 (en) * | 2021-03-29 | 2024-07-11 | Toray Industries, Inc. | Method for detecting microrna in biological sample, composition of hydrochloride of neutral amino acid, and container |
| KR102550113B1 (ko) * | 2021-05-28 | 2023-07-03 | 주식회사 시스바이오젠 | 전립선암 진단용 바이오마커 및 이의 용도 |
| CN114045344B (zh) * | 2021-12-09 | 2024-12-17 | 觅瑞（杭州）生物科技有限公司 | 前列腺癌诊断用尿液miRNA标志物、诊断试剂及试剂盒 |
| ES2995178A1 (es) * | 2023-07-31 | 2025-02-07 | Servicio Andaluz De Salud | Biomarcadores y método de diagnóstico de la diabetes monogénica en adultos jóvenes portadores de alelos HNF1A deletéreos |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2419129T3 (es) | 2007-09-14 | 2013-08-19 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo |
| EP2432895A2 (en) * | 2009-05-22 | 2012-03-28 | Asuragen, INC. | Mirna biomarkers of prostate disease |
| EP2496714B1 (en) | 2009-11-04 | 2016-08-31 | DiamiR, LLC | Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment |
| EP2341145A1 (en) * | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| SG186940A1 (en) | 2010-07-27 | 2013-02-28 | Genomic Health Inc | Method for using gene expression to determine prognosis of prostate cancer |
| EP2771487A1 (en) * | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| US9944991B2 (en) | 2012-11-02 | 2018-04-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies |
| WO2014085906A1 (en) | 2012-12-03 | 2014-06-12 | St. Michael's Hospital | Microrna biomarkers for prostate cancer |
| CA2834187A1 (en) * | 2013-04-15 | 2014-10-15 | Norgen Biotek Corporation | Use of micrornas for screening and diagnosis of prostate cancer and benign prostatic hyperplasia |
| CN103882118A (zh) | 2014-02-13 | 2014-06-25 | 绍兴市人民医院 | 用于检测前列腺癌的miRNAs |
| KR102669353B1 (ko) * | 2014-06-12 | 2024-05-28 | 국립연구개발법인 고쿠리츠간켄큐센터 | 전립선암 검출 키트 또는 디바이스 및 검출 방법 |
| EP3000895A1 (en) | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| US10480033B2 (en) * | 2015-01-14 | 2019-11-19 | Ohio State Innovation Foundation | MiRNA-based predictive models for diagnosis and prognosis of prostate cancer |
| EP3262186B1 (en) | 2015-02-27 | 2019-04-03 | QIAGEN GmbH | A microrna-based method for assessing the prognosis of a prostate cancer patient |
-
2016
- 2016-02-05 CA CA2976577A patent/CA2976577C/en active Active
- 2016-02-05 JP JP2017541256A patent/JP2018504915A/ja active Pending
- 2016-02-05 EP EP16706303.1A patent/EP3256602B1/en active Active
- 2016-02-05 US US15/550,416 patent/US10400288B2/en active Active
- 2016-02-05 WO PCT/DK2016/050032 patent/WO2016127998A1/en not_active Ceased
- 2016-02-05 ES ES16706303T patent/ES2749651T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2976577A1 (en) | 2016-08-18 |
| JP2018504915A (ja) | 2018-02-22 |
| EP3256602B1 (en) | 2019-09-04 |
| US20180030542A1 (en) | 2018-02-01 |
| ES2749651T3 (es) | 2020-03-23 |
| EP3256602A1 (en) | 2017-12-20 |
| US10400288B2 (en) | 2019-09-03 |
| WO2016127998A1 (en) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2976577C (en) | MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES | |
| EP3177739B1 (en) | Microrna biomarker for the diagnosis of gastric cancer | |
| EP3268494B1 (en) | Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) | |
| Veerla et al. | MiRNA expression in urothelial carcinomas: important roles of miR‐10a, miR‐222, miR‐125b, miR‐7 and miR‐452 for tumor stage and metastasis, and frequent homozygous losses of miR‐31 | |
| Babapoor et al. | Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing | |
| Chen et al. | Circulating microRNAs as promising tumor biomarkers | |
| Saldanha et al. | microRNA-10b is a prognostic biomarker for melanoma | |
| EP3262186B1 (en) | A microrna-based method for assessing the prognosis of a prostate cancer patient | |
| JP2011501966A (ja) | 結腸直腸癌監視のためのプロセス | |
| US20220267863A1 (en) | Compositions and methods for determining the prognosis of bladder urothelial cancer | |
| Mallick et al. | MicroRNAs and lung cancer: Biology and applications in diagnosis and prognosis | |
| MX2010012542A (es) | Metodos para evaluar el cancer colorrectal y composiciones para usar en el. | |
| CN110139936A (zh) | 口腔癌、咽癌和喉癌的生物标记 | |
| Khoshnevisan et al. | A significant upregulation of miR-886-5p in high grade and invasive bladder tumors | |
| Kumoğlu et al. | The biomarker features of miR-145-3p determined via meta-analysis validated by qRT-PCR in metastatic cancer cell lines | |
| WO2010018585A2 (en) | Compositions and methods for prognosis of melanoma | |
| HK40053634A (en) | Method of determining the risk of developing breast cancer | |
| HK1249555B (en) | Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |
|
| EEER | Examination request |
Effective date: 20201124 |